Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment

Laser-type device to be coupled with Stem Cell Therapy in Novel Treatment Approach

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

www.EntestBio.com

By controlling not only the intellectual property on a treatment method, but also the practical administration device itself, we are adding another layer of protection to the approach being developed.

San Diego (PRWEB) December 10, 2009

Entest Biomedical Inc. (OTCBB: ENTB) and Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced they have jointly entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system. It is anticipated this investigational medical device will be used in conjunction Entest’s patent pending adult stem cell therapies for treating patients with Chronic Obstructive Pulmonary Disease (COPD).

The goal of this proposed venture is to produce a laser-based therapeutic platform that increases levels of efficacy of stem cell therapy in patients with COPD. Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths in repairing damaged lung tissue of patients with COPD.

David Koos, President and CEO of Entest Biomedical, stated: “This LOI is the product of our previously announced discussions with manufacturers of laser-based therapies, in which we sought partners whose product portfolios and expertise matched Entest’s needs. By controlling not only the intellectual property on a treatment method, but also the practical administration device itself, we are adding another layer of protection to the approach being developed”

The activities contemplated in the letter of intent are subject to the parties entering into a definitive agreement, which is anticipated to occur shortly. Once such an agreement is reached, schematics, code, and intellectual property pertaining to the new device will be generated and owned by Entest. It is anticipated the laser system will be developed in Bio-Matrix’ Sorrento Mesa facility. This will be the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
info(at)EntestBio(dot)com
http://www.EntestBio.com

Follow the Company’s progress on Twitter:

http://twitter.com/Entest_BioMed

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

###


Contact

Past News Releases Group Rss Subscribe